[1] Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians
to prevent coronary heart disease: consensus statement of
the European Atherosclerosis Society[J].Eur Heart J, 2013,34(45): 3478-3490.
[2] 中华医学会心血管病学分会动脉粥样硬化及冠心病学组,中华心血管病杂志编辑委员会. 家族性高胆固醇血症筛查与诊治中国专家共识[J]. 中华心血管病杂志,2018,46(2):99-103.
[3] Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association[J].Circulation,2015,132(22): 2167-2192.
[4] Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and
clinical management. A position paper from the Consensus Panel on Familial
Hypercholesterolaemia of the European Atherosclerosis Society[J]. Eur Heart J, 2014,35(32): 2146-2157.
[5] Catapano AL, Graham I, Backer GD, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European
Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association
for Cardiovascular Prevention & Rehabilitation (EACPR) [J].Atherosclerosis,2016. 253: 281-344.
[6] Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial hypercholesterolaemia
in Australian communities[J].Int J Cardiol, 2015,185:69-71.
[7] Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial
hypercholesterolemia from the International FH Foundation[J]. J Clin Lipidol,2014,8(2): 148-172.
[8] de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of familial hypercholesterolemia in the 1999 to
2012 United States National Health and Nutrition Examination Surveys (NHANES)[J].Circulation,2016,133(11): 1067-1072.
[9] Pajak A, Szafraniec K, Polak M, et al. Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland[J].Arch Med Sci,2016,12(4): 687-696.
[10] Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial
hypercholesterolemia: a HuGE prevalence
review[J].Am J Epidemiol, 2004, 160(5): 407-420.
[11] Yuan G, Wang J, Hegele RA. Heterozygous
familial hypercholesterolemia: an underrecognized
cause of early cardiovascular disease[J].CMAJ,2006,174(8): 1124-1129.
[12] Bell DA, Watts GF. Response to familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice[J].Clin Cardiol,2014,37(6): 386-387.
[13] Shi ZM, Yuan BJ, Zhao D, et al. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a
community population[J].Int J Cardiol,2014,174(3): 834-836.
[14] Wang Y, Li Y, Liu X, et al. The prevalence
and related factors of familial hypercholesterolemia in rural population of
China using Chinese modified Dutch Lipid Clinic Network definition[J]. BMC Public Health, 2019, 19(1): 837.
[15] World Health Organization
Human Genetics Programme.Familial hypercho-lesterolemia-report of a second WHO consultation[R].Geneva:World Health
Organization, 1999.
[16] Teng HB, Gao Y, Wu CQ, et al. Prevalence and
patient characteristics of familial hypercholesterolemia in a Chinese
population aged 35-75 years: Results from China
PEACE Million Persons Project[J].Atherosclerosis, 2022,350:58-64.
[17] Li JJ, Li S, Zhu CG, et al. Familial
hypercholesterolemia phenotype in Chinese patients undergoing coronary
angiography[J].Arterioscler Thromb
Vasc Biol, 2017,37(3): 570-579.
[18] Sun D, Li S, Zhu CG, et al. Prevalence and
clinical features of familial hypercholesterolemia in Chinese patients with
myocardial infarction[J].Chinese Journal of Cardiology,2018,46(2): 109-113.
[19] Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia[J]. Nat Clin Pract Cardiovasc Med, 2007, 4(4):214-225.
[20] Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening
recommendations from the National Lipid Association Expert Panel on Familial
Hypercholesterolemia[J].J Clin Lipidl, 2011, 5(3):9-17.
[21] Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes
hypercholesterolemia[J].J Lipid Res,1990,31(8):1337-1349.
[22] Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9
for the treatment of dyslipidemia and atherosclerosis[J].J Am Coll of Cardiol,2013, 62(16):1401-1408.
[23] Chen GC, Zhu S, Hardman DA, et
al. Structural domains of human apolipoprotein B-100. Differential accessibility to limited proteolysis of B-100 in low density and very low density lipoproteins[J]. J Biol Chem,1989, 264(24):14369-14375.
[24] ACGS. Practice Guidelines for
the Evaluation of Pathogenicity and the Reporting of Sequence Variants in
Clinical Molecular Genetics[EB/OL].[2023-10-29].http://www.acgs.uk.com/media/774853/evaluation_and_re
porting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf.
[25] Raymond H, Maurice O, Victoria M, et al. The genetics and screening of familial hypercholesterolaemia[J].J Biomed Sci,2016, 23(1):1-12.
[26] Abifadel M, Varret M, Rabèset JP, et al. Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia[J].Nat Genet,2003,34(2):154-156.
[27] Benn M, Watts GF, Tybjærghansen A, et al. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General
Population Study estimated a prevalence of 1 in 217[J]. Eur Heart J, 2016, 37(17):1384-1394.
[28] Medeiros AM, Alves AC, Bourbon M. Mutational
analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement[J].Genet Med, 2016,18(4):316-324.
[29] Chiou KR, Charng MJ. Genetic diagnosis of familial hypercholesterolemia in
Han Chinese[J]. J Clin Lipidol, 2016,10(3):490-496.
[30] Yadav K. Sharma M, Ferdinand KF. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons[J].Nutr Metab Cardiovasc Dis, 2016, 26(10): 853-862.
[31] Abul-Husn NS, Manickam K, Jones LK, et al. Genetic
identification of familial hypercholesterolemia within a single U.S. health
care system[J].Science, 2016, 354(6319): aaf7000.
[32] Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and
clinical management. A position paper from the Consensus Panel on Familial
Hypercholesterolaemia of the European Atherosclerosis Society[J].Eur Heart J, 2014, 35(32): 2146-2157.
[33] Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial
hypercholesterolemia[J].Circulation, 2014, 129(9): 1022-1032.
[34] Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B
synthesis inhibitor, for lowering of LDL
cholesterol concentrations in patients with homozygous familial
hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial[J].Lancet, 2010, 375(9719): 998-1006.
|